Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021294 · ClinicalTrials.gov registry record · Phase 2
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00021294: Completed Phase 2 study, sponsored by University of Arizona.
NCT00021294 is a Phase 2 study that has completed, run by University of Arizona. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021294, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Eflornithine with or without triamcinolone may be effective in preventing nonmelanoma skin cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of eflornithine with or without triamcinolone in preventing nonmelanoma skin cancer in patients who have actinic keratosis.
Interventions
- DRUG eflornithine
- DRUG triamcinolone
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-05 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
What the finished NCT00021294 record still lists
NCT00021294 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which eflornithine is the first listed.
NCT00021294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021294 about?
NCT00021294 is a clinical study titled "Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Eflornithine with or without triamcinolone may be effective in preventing nonmelanoma skin cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of eflornithin...
What is the current status of trial NCT00021294?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00021294?
The interventions under investigation include: eflornithine (DRUG), triamcinolone (DRUG).
Who is sponsoring clinical trial NCT00021294?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia